ArticleJMA journal2026
Association between Coexisting Dementia and Mortality in Patients Receiving Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Nationwide Real-world Database Study.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for EGFR-mutated non-small cell lung cancer (EGFR-m NSCLC). Because these agents require sustained self-management, cognitive impairment may adversely affect treatment continuity and outcomes. However, the association between coexisting dementia and survival in patients receiving EGFR-TKIs remains unclear. Methods: This cohort study used a large Japanese administrative claims database. Patients aged ≥18 years with newly diagnosed NSCLC who initiated first-line EGFR-TKI therapy between 2018 and 2024 were included. Coexisting dementia was identified using diagnosis codes recorded before treatment initiation. The primary outcome was 3-year all-cause mortality. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs), adjusting for age, sex, body mass index, smoking status, comorbidity burden, functional status (Barthel Index [BI]), hypertension, dyslipidemia, and calendar year of treatment initiation. Results: Among 13,281 eligible patients, 282 (2.1%) had coexisting dementia. During follow-up, coexisting dementia was associated with higher all-cause mortality (aHR 1.35, 95% CI 1.06-1.73). In subgroup-specific analyses, preserved functional status (BI = 100) was associated with lower mortality among patients with dementia, whereas multiple clinical factors were associated with mortality among those without dementia. Conclusions: Coexisting dementia was associated with poorer survival among patients with EGFR-m NSCLC treated with EGFR-TKIs. Preserved functional status was associated with lower mortality among patients with dementia. These findings suggest that coexisting dementia may identify a clinically vulnerable subgroup in whom functional status warrants careful attention at the initiation of EGFR-TKI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.